PATENT CLAIM ANALYSIS

Application Number: 16040959
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-04
Patent Classification: ["424", "474000"]

Abstract:
Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.

Claim (Index 10):
The pharmaceutical dosage form of  claim 9 , further comprising:\n (a) about 165 mg of lactose monohydrate; (b) about 180 mg of microcrystalline cellulose; (c) about 50 mg of croscarmellose sodium; (d) about 10 mg of colloidal silicon dioxide; and (e) about 15 mg of magnesium stearate.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.3125
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15393847', '15885630', '15670283', '15282128', '14676370']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7002067098215127
- 35 USC 102 Novelty (BERT): 0.5583097979960131
- Combined Prediction Score: 0.6860170186389627
- Mean Citation Score: 296.9723180000001
- Max Citation Score: 455.52945
- Similarity Product: 334.55908946853884

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test